Emergent Biosolutions Inc (EBS) stock price

Emergent Biosolutions Inc (EBS) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NYSE. Price $6.80 (-3.13%), Market cap $0.44B, 52-week low–high $5.63 ~ $13.90.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease follow

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Emergent Biosolutions Inc are updated in real time on BlackAll Trade.

Emergent Biosolutions Inc financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Emergent Biosolutions Inc (EBS) stock price?

Emergent Biosolutions Inc trades at $6.80 (-3.13%). Real-time quotes and charts are available on BlackAll Trade.

What is the Emergent Biosolutions Inc (EBS) market cap?

Emergent Biosolutions Inc has a market cap of about $0.44B.

What does Emergent Biosolutions Inc (EBS) do?

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada